a Rett syndrome (RTT) is a neurodevelopmental disorder, primarily affecting girls. RTT causes severe cognitive, social, motor and physiological impairments and no cure currently exists. The discovery of a monogenic origin for RTT and the subsequent generation of RTT mouse models provided a major breakthrough for RTT research. Although the characterization of these mutant mice is far from complete, they recapitulate several RTT symptoms. This review provides an overview of the behavioural domains so far investigated in these models, including the very few mouse data concerning the developmental course of RTT. Both clinical and animal studies support the presence of early defects and highlight the importance of probing the presymptomatic phase for both the precocious identification of biomarkers and the early assessment of potential therapies. Preclinical evaluations of pharmacological and nonpharmacological interventions so far carried out are also illustrated. In addition, genetic manipulations are reported that demonstrate rescue from the damage caused by the absence of the methyl-CpG-binding protein 2 (MeCP2) gene even at a mature stage. Given the rare occurrence of RTT cases, transnational collaborative networks are expected to provide a deeper understanding of aetiopathology and the development of new therapeutic approaches.
Introduction
Rett syndrome (RTT) is a neurodevelopmental disorder, primarily affecting girls with a prevalence of one in 10 000 births. Classified together with autism into the Diagnostic and Statistical Manual of Mental Disorders (4th edition) in the group of the pervasive developmental disorders, RTT causes severe cognitive and physical impairments.
Although up to five variants have been identified so far, three quarters of the cases meet the diagnostic criteria for classic RTT (Hagberg, 2002) . One essential feature of RTT is an apparently normal prenatal and perinatal development until about 6-18 months of age, followed by a regression period, characterized by both a profound loss of acquired developmental skills in the areas of social contact, communication and hand use and a deceleration of head growth, usually leading to microcephaly.
At the end of this period, which is extremely variable in duration, lasting several years in some individuals, development reaches a plateau associated with a wide variety of RTT-specific symptoms. These include stereotyped hand movements, breathing irregularities, bloating, electroencephalogram abnormalities, sleep problems, gait dyspraxia, back deformities, feeding abnormalities as well as autistic-like behaviours (for a detailed review of symptoms see Mount et al., 2001; Hagberg, 2002) . During the last part of their life, RTT patients undergo a noteworthy worsening of motor performance. Lifespan is extremely variable and some individuals survive up to 70 years of age (Chahrour and Zoghbi, 2007) .
A monogenic origin for RTT was first proposed in 1999, when a mutation in the gene encoding methyl-CpGbinding protein 2 (MeCP2) was reported in a small number of RTT patients. Since then, more than 90% of classic RTT cases were found to have a mutation in this gene (Amir et al., 1999; Chahrour and Zoghbi, 2007) . X-linked dominant mode of inheritance characterizes the MeCP2 gene and accounts for the skewed sex ratio observable among RTT patients: RTT mainly affects girls as most of the hemizygous males as well as the homozygous females do not survive.
The MeCP2 gene encodes two closely related proteins binding to methylated CpGs acting as transcriptional repressors. They are believed to act through direct binding to the promoters of target genes or through chromatin remodelling mechanisms (Dragich et al., 2000; Jorgensen and Bird, 2002) . The mechanisms leading to the severe, progressive and specific neuronal dysfunctions when these genes are mutated are currently unknown. Several laboratories have proposed MeCP2-target genes including brain-derived neurotrophic factor (BDNF) (Chen et al., 2003; Martinowich et al., 2003) , corticotropin-releasing hormone (McGill et al., 2006) , a-thalassemia/mental retardation syndrome X-linked (Nan et al., 2007) , cyclin-dependent kinase-like 5 (Scala et al., 2005) , ubiquitin protein ligase E3A and g-aminobutyric acid (GABA) A receptor b 3 (Samaco et al., 2005) , FK506-binding protein 5 and Sgk1 (Nuber et al., 2005) , inhibitor of DNA-binding 1-4 (Peddada et al., 2006) , FXYD domain containing ion transport regulator 1 (Deng et al., 2007) , miR-184, a brain-specific microRNA (Nomura et al., 2008) , the distal-less homeobox 5 (Dlx5) and 6 (Dlx6) genes (Horike et al., 2005) (for overview, see also Chadwick and Wade, 2007) . Although not all of these targets are necessarily validated and some of them are controversial-Dlx5 has been disputed (Hogart et al., 2007; Schule et al., 2007) and data regarding ubiquitin protein ligase E3A have not been reproduced in independent studies (Makedonski et al., 2005; Jordan and Francke, 2006) , they are nonetheless accepted as potential targets by the RTT community, and intensively studied.
Despite a homogeneous genetic origin, both the severity of symptoms and the progression of the disease of the patients carrying a mutation in the MeCP2 gene can be extremely variable (Erlandson and Hagberg, 2005) . Different causes have been proposed to contribute to the great phenotypic variability among RTT patients. Different mutations have been described to determine different phenotypes. For instance, milder phenotypes have been found to be associated with C-terminal deletions, a type of mutation that accounts for about 10% of RTT cases, whereas early truncating mutations are responsible for more severe symptoms (Chahrour and Zoghbi, 2007) .
Moreover, in heterozygous females, X-linked genes are subjected to the X-chromosome inactivation phenomenon, where one of the two X chromosomes is randomly inactivated in every cell of the body. The RTT phenotype has been observed to vary depending on the number of cells expressing the wild type allele versus the mutated one. A skewed pattern favouring the wild-type (WT) allele would result in a milder phenotype (Hoffbuhr et al., 2002) .
No cure currently exists for this devastating syndrome. Only interventions aimed at improving condition and quality of life of RTT girls are at the moment available. These include rehabilitation interventions for the improvement of physical impairments (Lotan, 2007b) as well as alternative symptomatic interventions, ranging from pet therapy to acupuncture (for a review, see Lotan, 2007a) .
Two decades ago, 'gene targeting' procedures were developed for the introduction into predeterminated sites in the mouse genome of planned mutations (null mutations as well as more subtle changes which alter, but do not eliminate gene function). These advances in the field of genetics have led to the creation of mouse models with genetic aberrations characteristic of human clinical disorders (Tecott, 2003) .
In the case of RTT, after the identification of MeCP2 gene mutations as clear aetiological factors in about 90% of classical RTT cases, strategies using gene targeting have been used to generate several lines of mice carrying endogenous MeCP2 mutations (see section 'Description of the RTT mouse models with altered MeCP2 gene').
These mutant mice are at the moment regarded as good models of RTT for their high construct validity [i.e. the extent to which a model reproduces the aetiology and pathophysiology of a disorder (McKinney, 1984) ]. Moreover, although the behavioural characterization of these mutant mice is at the moment quite far from complete, indications are available suggesting a high face validity for the models [i.e. the degree to which a model resembles the symptoms of a disorder (McKinney, 1984) ], as MeCP2 mutant mice have been reported to recapitulate many RTT symptoms.
Complete and accurate phenotyping of these mutant mice could therefore offer a great opportunity to RTT research, as mouse models are expected to be enormously beneficial for determining the functional outcome and the effects on organic and cellular functions of gene mutations. In addition, a robust rodent model can have translational value in offering preclinical surrogate markers to evaluate treatment efficacy (Crawley, 2007) . This review provides a critical analysis of more recent advances in the behavioural phenotyping of RTT mouse models and illustrates the preclinical evaluations of new therapeutic approaches so far carried out.
Description of the Rett syndrome mouse models with altered methyl-CpG-binding protein 2 gene mouse studies, however, have focused on phenotypes of hemizygous male mice. This apparent discrepancy is primarily because of the unpredictability of heterozygous female phenotypes, deriving from the X-chromosome inactivation phenomena. In fact, the severity of symptoms is extremely variable in heterozygous females, depending on the number of cells expressing the WT allele versus the mutated one; the higher the ratio, the less severe the RTT phenotype. In addition, this variability seems to occur by chance. As a consequence, hemizygous male mice are at the moment considered the most suitable model to investigate the role of MeCP2 gene mutations on the development of RTT-like symptoms as they allow the elimination of the confounding effects of a variable phenotype. Innovative models should take into account the need to explore RTT phenotype within the constraints and/or possibilities provided by a more appropriate female-hormonal milieu.
The first RTT mouse models were described in the same 2001 issue of Nature Genetics from two different laboratories (Chen et al., 2001; Guy et al., 2001) . Guy et al. (2001) generated MeCP2-null mice lacking exons 3 and 4 (hemizygous males), thus blocking MeCP2 expression in the entire organism (MeCP2Bird). Chen et al. (2001) compared (i) a full knockout generated by the targeting deletion of exon 3 (MeCP2Jae), (ii) a conditional knockout carrying a Nestin-Cre transgene blocking embryonic MeCP2 expression selectively in the brain (CNS knockout), and (iii) a conditional knockout generated by the introduction of a CamK-Cre93 transgene blocking MeCP2 expression in the postmitotic neurons in the forebrain (forebrain knockout). Phenotypic differences among the three different lines were surprisingly limited, suggesting that most of the traits were because of the loss of MeCP2 gene function in the brain.
Subsequently, a RTT mouse model was described by Zoghbi's group. This expresses a truncated form of MeCP2 (MeCP2-308), a mutation commonly found in RTT patients (Chen et al., 2001; Shahbazian et al., 2002) .
Additional mutant mice have also been reported to resemble RTT symptoms. Little information is, however, currently available concerning those new and potentially interesting models. Among these, a selective basolateral amygdala loss of MeCP2 in adult mice (basolateral amygdala knockout) has been examined (Adachi and Monteggia, 2007) . A completely MeCP2-null mouse model, created by targeted deletion of the methylbinding domain of the MeCP2 gene (MeCP2Tam) (Pelka et al., 2006) , and another mouse model carrying a different (i.e. shorter) truncated form of MeCP2 gene (MeCP2-168) (Lawson-Yuen et al., 2007) , have also been described.
Interestingly, MeCP2 overexpression also produces RTTlike symptomatology in different transgenic lines (Collins et al., 2004) . This observation underlies the importance of a precisely regulated MeCP2 gene expression. In particular, different levels of MeCP2 gene expression have been observed to correlate with the severity of the RTT-like phenotype; the higher the MeCP2 gene expression, the earlier the onset of symptoms and the shorter the life span. Despite great variability in the progression of symptoms, all of the different transgenic lines display characteristic hindlimb clasping, kyphosis, aggressiveness and, to some degree, a premature death. Moreover, the transgenic line expressing MeCP2 at twofold WT levels (MeCP2-Tg1) also shows seizures, electroencephalogram abnormalities, decreased anxietylike behaviours, and hypoactivity, as well as enhanced learning of motor skills, hippocampal learning and synaptic plasticity.
Onset of symptoms, life span and general health Different developmental phases can be identified in the RTT mouse models described so far as well as in RTT patients. All of them show an early developmental phase where no obvious deficits (i.e. visible by gross examinations) can be detected ( Fig. 1 ) and after the onset of symptoms undergoes an escalating worsening until the premature death.
In the MeCP2Bird model (Guy et al., 2001) , male and female mice appeared normal until the 3rd postnatal week; thereafter both sexes developed gross abnormalities (with a sexually dimorphic time course) consisting of a stiff, uncoordinated gait and reduced spontaneous movements. Most animals subsequently developed hindlimb clasping and irregular breathing. Uneven wearing of the teeth and misalignment of the jaws were also frequent. Testes of MeCP2-null mice were always internal. A distinct feature of the phenotype was varying body weight, which was dependent on genetic background (C57BL/6 gave rise to underweight animals, whereas, after crossing to a 129 strain, F1 animals became heavier than siblings after 8 weeks of age). In MeCP2Bird hemizygous males, variable progression of symptoms occurred between the 4th and 7th postnatal week leading to rapid weight loss and death (around 8th postnatal week) (Fig. 1) . In contrast, females initially showed no symptoms and raised normal litters, and only later, after the 12th postnatal week, acquired inertia and hindlimb clasping phenotypes. More pervasive unambiguous symptoms (e.g. irregular breathing) were present only in one half of the heterozygous females by 9 months.
In the MeCP2Jae model, the onset of symptoms has also been extensively described (Stearns et al., 2007) . As early as 4 weeks of age mutant male mice could be occasionally identified by an altered gait. A significant loss of body weight, body tremors and shaking paws were evident by 5 weeks of age, whereas piloerection and periods of laboured breathing were noted as early as 6 weeks of age. Heterozygous mutant females, although their body weight was slightly reduced compared with WT females by 5 weeks of age, seemed normal for the first 4 months and began to show symptoms such as reduced activity and ataxic gait at a later stage. In association with the appearance of symptoms, females were also reported to gain weight. Piloerection, hindlimb clasping and heavy breathing took 6 months or longer to develop.
Mice with a truncated mutation (MeCP2-308) similarly recapitulated many RTT features (Shahbazian et al., 2002) . Mutant male mice exhibited no apparent abnormalities until around 6 weeks of age, when tremors were detectable while suspending mice by the tail. At 4 months of age, tremors were apparent by visual observation alone. After 5 months of age, 40% of animals developed kyphosis, and after 8 months of age the fur of mutant mice was noticeably more oily and dishevelled than that of WTs. Spontaneous behavioural myoclonic jerks and seizures were observed in several mutant mice.
Body weight was within the normal range and mice were fertile. Truncated MeCP2-308 male mice were anecdotally reported to rapidly and repeatedly move their forelimbs, often bringing them together and sometimes holding them together for several seconds when they were undisturbed in their home cage or suspended by the tail. Moreover, Young and Zoghbi (2004) reported that as early as 6 weeks of age mutant male mice developed periocular inflammation and bleeding usually accompanied by bacterial infections. In a mixed background (129SvEv Â C57BL/6), Moretti et al. (2005) observed ataxia and breathing abnormalities. Most MeCP2-308 male mice survived for at least 1 year of age, whereas heterozygous female mice displayed milder and variable features starting from 1 year of age (Fig. 1) .
Although their characterization is far from complete, the other RTT models have also been reported to recapitulate RTT symptoms. In the forebrain knockout, for instance, no obvious initial phenotypic differences were noted between hemizygous mice and sex-matched controls. At 16 weeks of age, however, mutant mice Costitutive KO M MeCP2Bird (Guy et al., 2001 ) F M MeCP2Jae (Chen et al., 2001 became heavier than WT and started showing hindlimb clasping. In addition, weight went on increasing as they became older (Gemelli et al., 2006) .
In another MeCP2-null model, the MeCP2Tam, depending on the background, hemizygous male mice were reported to survive up to 20 weeks of age. Unusual gait, hindlimb clasping, dishevelled fur, laboured breathing, tremors and seizures were observed in this mouse model. At about 5 weeks of age, hemizygous male mice start failing to thrive. No differences between heterozygous and WT females were evident until 13 weeks of age (Pelka et al., 2006) .
A longer life span has been observed in the truncated MeCP2-168 model. Hemizygous male mice have been reported to survive until about 12 weeks of age and to show, by 7 weeks of age, significant hindlimb atrophy and clasping, hypoactivity and breathing irregularities . Interestingly, forelimb stereotypies have been reported for this mouse model as well as for the MeCP2-308 (Lawson-Yuen et al., 2007) . Heterozygous females showed significant symptoms (i.e. hindlimb clasping and breathing irregularities) by approximately 6 months and survived more than 1 year.
In basolateral amygdala knockout mice, no obvious abnormalities in overall health have been detected so far. A detailed behavioural phenotyping of this potentially new mouse model is currently in progress (Adachi and Monteggia, 2007) .
Age at onset of symptoms varied widely in those models, with earliest onset in MeCP2Bird male mice (3 weeks), and latest in truncated MeCP2-308 hemizygous mice. The same is true for life span with MeCP2Bird mice living till the 8th postnatal week. Figure 1 shows the progression of the disease in the different mouse models so far available. Interestingly, motor stereotypies have been reported in all the models, but they involve forelimbs only in the two models carrying truncated mutations of MeCP2 gene.
Breathing profiles
Although respiratory impairments have been anecdotally reported for all the mouse models, a more accurate analysis of breathing patterns has been performed in the MeCP2Bird and the CNS knockout models only (Viemari et al., 2005; Bissonnette and Knopp, 2006) .
Plethysmographic recordings of unrestrained MeCP2Bird mice highlighted a progressive worsening of breathing disturbances since their appearance at 1 month of age (Viemari et al., 2005) . In particular, alternating periods of fast and slow respiratory frequencies as well as apnoeas of variable durations were reported in knockout male mice at 6 weeks of age. One week later, mice worsened and showed a significant reduction in mean breathing frequency accompanied by very frequent long lasting apnoeas.
More recently, breathing patterns of heterozygous females from both knockout and CNS conditional knockout models have been investigated to evaluate the effects of the organ distribution of MeCP2 deficiency (Bissonnette and Knopp, 2006) . When studied under hypoxic conditions at about 5 months of age, both the models showed hyperventilation, but only knockout females showed subsequent respiratory depression followed by a prolonged apnoea. A ubiquitous deficiency of MeCP2 seems therefore to be necessary to observe this breathing pattern.
Interestingly, the depression observed to follow hyperventilation in knockout females was no longer prominent if 4% carbon dioxide was added to the hypoxic gas mixture. These results, together with the observation that tidal volume and lung volume in knockout mice were larger than in controls, would suggest, according to the authors, that the peculiar response of knockout females to hypoxia could be because of hypocapnia, a diminished concentration of carbon dioxide in the blood (Bissonnette and Knopp, 2006) .
In addition to the in-vivo studies, an analysis of the breathing phenotype of MeCP2Bird mice has been performed using the perfused working heart-brainstem preparation (Stettner et al., 2007) . This technique has allowed the identification of a dysfunction of the central and vagal postinspiratory activity in this RTT mouse model, which could potentially explain most of the respiratory abnormalities that affect RTT patients.
The earlier the better: phenotyping the presymptomatic phase Particularly in models of neurodevelopmental disorders, it seems critical to conduct behavioural phenotyping during the developmental period, to document precisely the onset of symptoms, examine transient signs and provide a basis for the timing of early intervention. Moreover, in transgenic and knockout mice, developmental analysis can shed light on gene effects not accessible when studying adulthood alone. Behavioural testing during ontogeny can help our understanding of how a genetic manipulation affects central nervous system function in ontogeny and it can represent an appropriate strategy to identify possible compensatory and/or unexpected effects (Branchi and Ricceri, 2002) .
These considerations become particularly relevant for RTT. Both RTT patients (Hagberg, 2002) Fig. 1 ) have been reported to show an apparently normal period before clinical symptoms start to develop, and this feature of the disease is currently one of the diagnostic criteria for RTT (Diagnostic and Statistical Manual of Mental Disorders for the fourth and current edition). Increasing evidence from both clinical and animal studies, however, supports the presence of earlier defects (i.e. during that developmental phase earlier regarded as asymptomatic) (Kerr et al., 1987; Charman et al., 2002; Picker et al., 2006) .
Studies of family home videos, recorded before the disorder was clearly manifested (Kerr et al., 1987; Charman et al., 2002) , confirm that girls with RTT, during the first months of life, are not so asymptomatic as was thought. Motor deficits during the first 6 months of life (e.g. abnormal general movements and finger movements) (Einspieler et al., 2005) as well as alterations in communicative behaviours during the first 2 years of life (e.g. limited gestural communication) (Tams-Little and Holdgrafer, 1996) have been reported. According to Kerr and Prescott (2005) developmental delays and preregression abnormalities correlate in RTT girls with the severity of symptoms shown later during development.
In RTT mouse models, early molecular and cellular impairments have been described. Specifically, an imbalance between inhibitory and excitatory synaptic transmission in the ventrolateral medulla (i.e. a strong depression in GABAergic synaptic transmission) was reported in the MeCP2Bird model starting as early as postnatal day (PND) 7 (Medrihan et al., 2007) . MeCP2Bird mice at 2 weeks of age were also reported to display an increased number of glutamatergic synapses (Chao et al., 2007) . Overexpression of genes that are induced during the stress response by glucocorticoids was highlighted in early symptomatic as well as in presymptomatic knockout male mice (Nuber et al., 2005) . In addition, Viemari et al. (2005) suggested that central respiratory deficits in knockout mice may arise early during development. Although obvious breathing abnormalities (i.e. irregular breathing rhythm) were not fully displayed before 1 month of age, in-vitro recordings in medullary slices obtained from MeCP2Bird mice at PND 14-21 revealed an increased variability in the duration of respiratory cycle that was also associated with a significant reduction of norepinephrine content. The rhythm produced by such isolated respiratory network was stabilized by exogenous norepinephrine application, confirming this hypothesis.
Anatomical as well as functional modifications have also been reported during the presymptomatic phase in RTT mouse models, which provide important hints at neurobehavioural dysfunctions that precede the noticeable behavioural changes. In particular, volumetric changes in certain brain areas have been reported to be evident already during the presymptomatic phase in both MeCP2Bird and MeCP2Jae mice (Saywell et al., 2006; Stearns et al., 2007) . Both these models presented an overall reduction in brain size, but a significantly reduced volume has been reported for the motor cortex and the corpus callosum in the MeCP2Bird mice of 5-8 weeks of age (Saywell et al., 2006) and for the amygdala, the hippocampus and the striatum in MeCP2Jae mice at PND 35 (Stearns et al., 2007) . A longitudinal study (from birth to PND 42) on the concentrations of major neurotransmitters in the brain of MeCP2Bird mice reported smaller concentrations of biogenic amines in the brain of mutant mice when compared with WT. Interestingly, this difference became larger with increasing age. Brain concentration of GABA was also reported to be altered, but the difference between mutant and WT mice did not show clear age dependency (Ide et al., 2005) . Moreover, the modifications observed in symptomatic MeCP2Jae mice in BDNF expression and cortical synaptic plasticity were confirmed in presymptomatic mice (Dani et al., 2005; Chang et al., 2006) . Different results have been obtained regarding hippocampal synaptic plasticity, which was impaired in symptomatic mutant mice (MeCP2Bird and MeCP2Jae) but showed no significant changes during the presymptomatic phase (Asaka et al., 2006) . More recently, a comparative study between MeCP2Bird and MeCP2Jae mice described morphological changes in early neuronal morphology (Belichenko et al., 2008) . Interestingly, brain regionspecific changes were clearly defined during the presymptomatic phase, but were not always similar in the two models.
These results suggest that some subtle alterations are already evident in both RTT patients (before the preregression period) and mouse models, so that better investigation and characterization of the presymptomatic phase in RTT mouse models could be extremely worthwhile. As a matter of fact, detailed developmental analysis in such models, exploiting the already mature methodology of behavioural and physiological phenotyping (Branchi and Ricceri, 2002) , can provide an early window of opportunity on which potential therapeutic strategies could be tested. Starting from the early phases of development would make a potential rescue more likely. Moreover, the identification of precocious altered patterns is crucial for the identification of early behavioural and molecular markers to be used as early diagnostic tools. So far, however, besides the abnormal ultrasound vocalizations evidenced during the first postnatal week in MeCP2Jae mice (Picker et al., 2006) , few data are available concerning the behavioural development of RTT mouse models.
Neonatal phase
To date, behavioural phenotyping of RTT mouse pups has been conducted only in MeCP2Bird and MeCP2Jae models (Picker et al., 2006; Santos et al., 2007) (Table 1 , section: Neonatal phase). A behavioural phenotyping of truncated MeCP2-308 pups is, however, currently in progress (Ricceri et al., 2007) .
For MeCP2Bird pups, the analysis conducted by means of a scale adapted to very young rodents, which can verify the onset and maturation of a series of single reflexes and motor skills (Fox, 1965; Bignami, 1996; Ricceri et al., 2007) , from PND 4 to 21, revealed a delay in the acquisition of the postural and negative geotaxis reflexes in mutant pups of both sexes. In female pups only a significant reduction of body weight (in line with adult data) and impaired righting reflex were found when compared with WT littermates (Santos et al., 2007) .
For MeCP2Jae pups, a similar analysis revealed that overall somatic growth did not differ between mutant mice and sex-matched WT controls. Righting, forelimb grasping, forelimb placing, vertical-screen test and geotaxis did not differ between WT and sex-matched mutants. A mutation-associated transient delay was, however, noted, when performing the cliff aversion test, the hindlimb grasping and placing, and the level-screen reflex, with slight sex-different profiles.
Interestingly, in PND 5 MeCP2Jae males there was a more than three-fold increased emission in ultrasonic vocalizations and a different pattern of calls throughout the 1st postnatal week compared with WT controls. Females also showed an increase in ultrasonic vocalizations during the whole 1st week with a peak on PND 7 (Picker et al., 2006) . These kinds of vocalizations are emitted by pups when separated from the mother. They are considered a precocious and reliable index of pups' communicative/social behaviour, and are also thought to provide a window on emotional/affective condition early in development (Moy and Nadler, 2008; Scattoni et al., 2008) .
Postweaning presymptomatic phase
Onset of symptoms in RTT mouse models has been described to be extremely variable depending on the kind of MeCP2 mutation (Fig. 1) . As a consequence, the presymptomatic phase can overlap with the neonatal one, as in the case of the MeCP2Bird model (Guy et al., 2001) , or it can last longer [e.g. up to 6 weeks of age in the truncated MeCP2-308 (Shahbazian et al., 2002) ].
Yet, except from the two studies mentioned above (Picker et al., 2006; Santos et al., 2007) , that actually found some early impairments in neonatal knockout mice (for details, see 'Neonatal phase' and Table 1), other analyses have not been carried out so far to evaluate the presence of early behavioural deficits detectable before the onset of obvious symptoms in RTT mouse models (Table 1) .
Paucity of developmental data is likely because of the fact that, to carry out such studies early during development, many variables need to be considered in the experimental design. These include the necessity to investigate and score blind mouse pups of an unknown genotype. In addition, the behavioural assessment is based on a limited behavioural repertoire characteristic of pups' ontogenetic niche (Spear, 1990; Bignami, 1996) . Furthermore, unavoidable manipulations by the experimenter, such as repeated handling or maternal separation, have to be minimized to reduce stressful events for pups and dam (Moy and Nadler, 2008) .
Motor performance
In MeCP2Bird mice only a reduced latency to fall off the rotarod (a paradigm mostly used for evaluating motor skills) at 5 weeks of age in both sexes, indicative of a hindlimb coordination deficit, has been highlighted (Santos et al., 2007) . More information is available for MeCP2Jae mice: they start to exhibit severe motor deficits compared with WT, by 5 weeks of age. One week later, during the dark cycle, mutant mice of both sexes were less active and made fewer ambulatory movements than their sex-matched WT controls. Abnormalities in grip strength, reduced motor coordination assessed by rotarod testing, and severely impaired swim performance were also reported (Stearns et al., 2007) .
In MeCP2-308 mice, motor abnormalities are definitively more subtle. When assessed for motor deficits at 8-10 weeks of age, using a variety of tests, mutant male mice did not show significant impairments in exploratory behaviours, locomotion or coordination, apart from shorter latencies to drop in the wire suspension test (Shahbazian et al., 2002; Moretti et al., 2005) . After 3 months of age, however, motor deficits were evident in the dowel test, vertical pole test and in a modified version of the rotarod (rod covered with duct to prevent gripping) (Shahbazian et al., 2002) . Less locomotor activity in an open field has also been reported. Although similar speed and amount of rearing have been observed, both total distance travelled and time spent moving progressively reduced during the subsequent three intervals of 10 min (Shahbazian et al., 2002) .
Mild abnormalities in circadian motor activity were also detected in MeCP2-308 mice, namely a decrease of activity in the dark phase associated with light-phase hyperactivity. Mutant male mice also show a significant impairment in nesting behaviour in the home cage that, according to the authors, could correspond to the apraxia of hand use seen in RTT patients, because in the same animals motor deficits were excluded (Moretti et al., 2005) . As for the forebrain knockout mice, the rotarod test, when performed at both 12 and 16 weeks of age, revealed an impairment of these mutant mice in motor coordination (Gemelli et al., 2006) . Although, as mentioned above, all the RTT mouse models have been reported to show limb stereotypies, no attempt to fully and formally characterize these interesting motor deficits has been carried out so far.
Sensory abilities
Sensory abilities seem to be basically spared in the main RTT mouse models. In MeCP2Bird mice, no significant genotype-based differences were reported (Guy et al., 2001) . Similarly, in MeCP2Jae mice no sensory deficits were detected in visual acuity, shock reactivity and auditory acuity (Stearns et al., 2007) and no hearing or pain sensitivity alterations were found in the forebrain knockout model (Gemelli et al., 2006) . In truncated MeCP2-308 mice, the performance in the buried food test (matching control levels) excluded olfactory deficits in male subjects (Moretti et al., 2005) . Threshold current intensity values required to elicit stereotyped behavioural responses also did not differ between mutant and WT male mice (Moretti et al., 2006) .
Anxiety-like behaviours
Anxiety profile did not seem to be altered in 4-week-old (both mutant male or female mice) MeCP2Bird mice tested in both open field and in the elevated plus-maze tests (Santos et al., 2007) . In contrast, anxiety profiles in MeCP2Jae mice appeared altered at 8 weeks of age, but the effect of the genotype was rather unclear (Stearns et al., 2007) . Although mutants spent more time than controls in the open arms of both the zero maze and the elevated plus-maze, they also spent a greater amount of time freezing on zero maze.
At 4-6 months of age, increased anxiety-like behaviours were also evident in forebrain knockout mice when tested in the elevated plus-maze as well as in the open field (Gemelli et al., 2006) . The same tests have also highlighted an impairment in MeCP2-308 mice (Shahbazian et al., 2002) . Moreover, McGill et al. (2006) reported that increased anxiety-like behaviours were accompanied by an enhanced physiologic response to stress in MeCP2-308 male mice at 4 months of age. The authors detected a decrease in time spent in (i) centre of the arena of an open field; (ii) open arms of an elevated plus-maze; and (iii) lit side of a light/dark box, all these effects not being attributable to hypoactivity or motor impairment.
Cognitive abilities
Rather surprisingly, no data are available on cognitive performance of MeCP2Bird mice although a series of different learning and memory tests were administered to the other models. In MeCP2Jae mice, a detailed behavioural analysis revealed severe (but not global) cognitive impairments at 6-8 weeks of age; mice of both sexes were impaired in recognition of a spatial change in an open field; mutant male mice (not heterozygous female mice) exhibited a selective cued fear conditioning deficit, whereas fear conditioning contextual memory was intact. Navigational abilities were so dramatically impaired that it was not possible to disassociate motoric from cognitive deficits in water maze tasks (Stearns et al., 2007) .
Significant alteration in learning and memory performance was also clearly evident in MeCP2-308 mice, but these cognitive deficits appeared after the 20th week of age, that is, significantly later that in the MeCP2Jae mice. The deficits consisted of a slower acquisition rate in the Morris water maze, associated with a spatial memory deficit in the same task. A significant contextual memory deficit of a conditioned fear response was also reported. In addition, in a long-term social memory test, mutant male mice showed a social recognition deficit after single or repeated exposures to a juvenile male (Moretti et al., 2006) . It is worth noting that in the original report by Shahbazian et al. (2002) , no alterations had been found in the Morris water maze and the conditioned fear test. Two factors have been proposed by Moretti et al. (2005) to account for the different results: differences in the genetic background (highly mixed 129/ SvEV ÂC57BL/6 vs. pure 129/SvEv, respectively) and the intensity of the training protocol (more vs. less intense). This discrepancy highlights the importance of taking into account background effects.
Interestingly, at 4-6 months of age forebrain knockout mice exhibited a significant reduction in time spent in a cue-dependent fear conditioning, but they were not impaired in a context-dependent fear conditioning (Gemelli et al., 2006) . On the account of the involvement of different brain areas in the execution of these tests (hippocampus and amygdala vs. amygdala, respectively), these results suggest that the hippocampus, but not the amygdala, is impaired in this RTT mouse model.
Social behaviours
Little information is available concerning social deficits in RTT mouse models except in MeCP2-308 and forebrain knockout mice (Shahbazian et al., 2002; Moretti et al., 2005; Gemelli et al., 2006) .
In MeCP2-308 mice, social behaviour has been intensively studied, including nest building (Moretti et al., 2005) . Mutant males exhibited task-dependent deficits, likely because of reduced social motivation. When comparing single-housed mutant and WT male mice, at 8 weeks of age no significant differences in aggression levels were seen in either the resident-intruder test or the tube test. Significant differences between the two genotypes only emerged at 30 weeks of age, when levels of social interaction of mutant male mice with both familiar and unfamiliar mice were significantly lower than WT controls. Such diminished social performance seems rather selective as it occurred in the absence of both social recognition and olfactory deficits.
The results obtained by Shahbazian et al. (2002) in MeCP2-308 male mice of mixed background are again quite different. When tested in the tube test at 5 months of age, WT actively avoided mutant animals, whereas MeCP2-308 male mice did not significantly retreat. Moreover, no significant differences were found in the resident-intruder test as both genotypes behaved similarly towards novel intruders. WT mice, however, showed less sniffing and spent less time interacting depending on the genotype of the resident; a significant decrease in social interactions was observed if the resident was a mutant (Shahbazian et al., 2002) .
Two social interaction procedures aimed at measuring social interest and social recognition have been used to assess whether the forebrain knockout male mice at 4-6 months of age showed social deficits (Gemelli et al., 2006) . Impairment was highlighted in both tests, even when a juvenile mouse, an unthreatening stimulus, was involved.
Preclinical evaluation of new therapeutic approaches Genetic manipulations
Different laboratories have used genetic manipulation of RTT mouse models. The techniques that were used, despite their applicability to patients as therapeutic approaches, are at the moment quite far from being achievable in a clinical setting, have been extremely important in investigating whether the damage caused by the absence of MeCP2 during development is reversible when MeCP2 function is restored at adulthood. So far, two different strategies have been adopted. Table 2 summarizes all the attempts that have been made so far.
Different transgenic mouse lines have been generated to evaluate whether restoring normal levels of MeCP2 perinatally by the insertion of a transgene could at least partially rescue the RTT-like phenotype of the model. The effects of the transgene activation were investigated when MeCP2 expression involved different brain areas and populations of neurons.
In the earliest of these studies (Luikenhuis et al., 2004) , a mouse expressing functional MeCP2 specifically in postmitotic neurons from embryonic day 10, was generated. The authors reported that hemizygous male mice showed increased life span, but at 6-15 weeks of age were generally less active than WT controls.
In contrast, no improvement of symptoms was observed in hemizygous male mice of two other RTT models Weight (throughout postnatal development), locomotor activity (between 4 and 7 months of age) and brain weight (at 5 months of age) were undistinguishable from WT (MeCP2Bird and truncated MeCP2-308) when the expression of functional MeCP2 was restricted to either the forebrain or the cerebellum and the striatum (Alvarez-Saavedra et al., 2007) .
Recently, Jugloff et al. (2008) investigated whether the expression of a MeCP2 transgene in the forebrain of heterozygous female mice could positively affect their phenotype. It must be noted that in heterozygous females, some of the cells, because of the process of random X inactivation, can already express endogenous MeCP2. This strategy turned out to be beneficial in improving some of the symptoms in heterozygous females of 9-12 months of age. This result seem surprising as it is now widely acknowledged that even a moderate overexpression of MeCP2 can be associated with neurological impairments (Collins et al., 2004) Table 2 .
It is worth noting that good results (i.e. delayed onset of symptoms) have been obtained even when a BDNF transgene was inserted in the genome of a knockout mouse model (Chang et al., 2006) . Low levels of BDNF, which is encoded by one of the target genes of MeCP2 (Chen et al., 2003) , have been found to characterize symptomatic MeCP2Bird mouse brains (Chang et al., 2006) . Interestingly, this study is in line with other preclinical evaluations of therapeutic approaches (e.g. ampakine treatment and environmental enrichment strategies; Table 2 ) pointing to an association between improvements in RTT phenotype and significant increases in brain BDNF levels. Taken together those studies underlie the importance of looking for interventions aimed at restoring WT-like levels of BDNF as potential therapeutic approaches.
In addition to generation of transgenic mouse lines, some authors have investigated whether the reversal of symptoms could be achieved by reactivating the function of the endogenous MeCP2 gene, originally silenced by the insertion of a 'lox-Stop' cassette. The effects of this reactivation were examined in two different mouse models, each of them expressing MeCP2 at different ages.
In the MeCP2Jae mouse model (Giacometti et al., 2007) , four different Cre transgenic lines were used to obtain the reactivation of the MeCP2. All of those lines express Cre recombinase that reactivates MeCP2 perinatally, but differ because of the brain areas where this recombinase is activated. Importantly, all the 'rescued' male mice showed a lengthened life span and some of them also showed improvements in the different parameters investigated (Table 2 , panel: Genetic manipulations).
In the MeCP2Bird mouse model (Guy et al., 2007 ) the reactivation of MeCP2 in the brain was induced through weekly injections of the oestrogen analogue tamoxifen. The injections started when the animals were already symptomatic. Scoring once a week the animals for six of the most evident symptoms (e.g. tremors) from birth to death, the authors highlighted a significant reduction in the aggregate symptom scores in the treated hemizygous mice when compared with the untreated mutant males. Moreover, MeCP2 reactivation in heterozygous females resulted in a complete reversal of the deficit in hippocampal long-term potentiation, which had been observed to accompany the onset of symptoms in such a model (Guy et al., 2007) .
None of those studies, however, included a detailed behavioural phenotyping of 'rescued' mice, which would allow exploration of the effects of such strategies on a wider range of RTT symptoms. The low interest devoted in those studies to detailed behavioural testing that would verify even subtle improvements achieved by the genetic rescue, emphasizes the importance of creating networks of laboratories with differential expertise for a more complete understanding of the disease.
Pharmacological treatments
Although the disabilities that affect RTT girls are extremely numerous, respiratory abnormalities are considered among the most devastating. These are in fact responsible for up to 26% of the deaths among RTT patients (Kerr et al., 1997) . Nevertheless, no treatments aimed at improving this vital function are currently available for RTT patients. Most current research effort, however, focuses on drugs that can be used for the treatment of those symptoms. Indeed, two different preclinical pharmacological interventions have been recently proved to ameliorate breathing in RTT mouse models.
Desipramine, an antidepressant drug which blocks norepinephrine uptake has recently been reported to produce beneficial effects on the respiratory function of MeCP2Bird male mice. In addition, a lengthened life span was reported for mutant animals when the treatment was administered both orally in drinking water (Zanella et al., 2008) or through daily injections (Roux et al., 2007a) .
Interestingly, when the treatment started at an early symptomatic stage (in drinking water, from PND 30) a delayed evolution of breathing symptoms was observed, whereas if it started with daily injections when the animals were already clearly symptomatic and showed 100 apnoeas per hour, a significant reduction in apnoea was observed. These results stress the importance of looking for early therapeutic interventions (i.e. during the early symptomatic or presymptomatic phase of the disease). As a matter of fact, although both kinds of treatments resulted in a lengthened life span, knockout mice, when treated during the early symptomatic phase, experienced longer asymptomatic periods and, apparently, an improvement in their 'quality of life', a worthwhile result for a therapy.
The data obtained in this mouse model suggested that the noradrenergic system could be involved in the RTT pathophysiology and that its pharmacological stimulation could be of therapeutic value. As a result of these encouraging results, the authors, have started a clinical trial but results are not yet available (Roux et al., 2007b) .
Ampakines are a family of small molecules that trigger short-term increases in the duration of AMPA-mediated inward currents and thereby enhance the activation of glutamatergic AMPA levels (Nagarajan et al., 2001) . As a consequence of repeated ampakine treatments, the activity-dependent expression of BDNF is enhanced both in vitro and in vivo (Lauterborn et al., 2000; Rex et al., 2006) . In fact, hemizygous MeCP2Jae mice showed a 42% increase in BDNF protein content in no dose cranial sensory ganglia, 3 days after they started to be treated with this drug, at around PND 35. Moreover, this increase was accompanied by a sharp decrease of the episodes of high breathing frequency (Ogier et al., 2007) , raising the possibility of an application of this class of compounds as a treatment for breathing dysfunctions in RTT patients.
Nonpharmacological interventions
Clear evidence for epigenetic processes in autism spectrum disorders is now available (Schanen, 2006) . As for RTT, the involvement in the disorder of the MeCP2 gene (Amir et al., 1999) , a key epigenetic regulatory factor, has highlighted the potential role of epigenetic factors in the aetiology of such syndrome (Bienvenu and Chelly, 2006; LaSalle, 2007) .
Emerging therapeutic approaches from animal models of several neurological disorders would suggest a potential therapeutic value for epigenetic factors. Dietary supplementation, for instance, is a strategy with high translational value that has been tried in a number of neurodevelopmental disorders (Down syndrome, attention deficit hyperactivity disorder, and autism) (Bell et al., 2004; Portwood, 2006; Scala et al., 2006) . Moreover, data from animal models indicate that being reared in an enriched environment, which provides animals with additional physical and social stimulation, has been shown to reverse or improve the altered phenotype in different neurobehavioural diseases, including genebased neurodegenerative syndromes as well as early environmental-induced insults (e.g. gestational ethanol or stress exposures) (Laviola et al., 2004; Darnaudery and Maccari, 2008) .
A first step towards the assessment of both these different epigenetic approaches has been recently made in mouse models of RTT. A perinatal supplementation with choline, an essential nutrient classified as one of the B-complex vitamins, and the acetylcholine precursor in cholinergic neurons, has been reported to reverse in mutant mice both the deficits of the cholinergic function as well as the cognitive dysfunctions that are typically associated with RTT .
When tested at PND 34-36, MeCP2Jae mice that had received choline from their lactating dams supplemented with choline in drinking water, showed improved motor coordination and locomotor activity (Nag and BergerSweeney, 2007) . In fact, an abnormal in-vivo choline signal has been highlighted in the brain of MeCP2 knockout mice (Saywell et al., 2006) , although which components of this signal are altered has not been determined. Interestingly, choline also represents an important source of methyl groups from the diet, thus affecting DNA methylation (Zeisel, 2006) . A systematic evaluation of the effects of a methyl-donor diet in RTT mouse models, however, has not been performed so far. This is particularly relevant as MeCP2 gene is involved in methylation-specific transcriptional repression. Abnormalities associated with RTT might therefore result from dysregulated gene expression, which could be exacerbated by inappropriate DNA methylation (Schanen, 2006) . It is worth noting that clinical trials for RTT patients have been conducted involving the methyldonors folate and betaine. No objective improvement was reported, but parents did describe increased alertness and interaction in patients receiving the active agents (from IRSF web site, 2007).
These results support the need for a systematic preclinical evaluation of the effects of those nutritional factors. As a matter of fact, understanding the interactions and underlying mechanisms between nutrition and the genetics of RTT could provide insights into the root causes of the disorder and provide opportunities for innovative treatments.
A few, still preliminary, indications are also available on the beneficial effects of environmental enrichment in two MeCP2 knockout RTT mouse models (Moriuchi et al., 2007; Pizzorusso et al., 2007; Ward et al., 2007) . Enrichment of the rearing environment upregulates the expression of more than 100 genes that are concerned with synaptic composition, and increases neurogenesis in the hippocampus (Rampon et al., 2000) . In addition, physical environmental enrichment has been shown to positively modulate most neurobehavioural, endocrine and immunological alterations deriving from early genetic or environmental adverse conditions (MorleyFletcher et al., 2003; Laviola et al., 2004) . Importantly, a key long-term effect of enriched living is one already reported to produce good results (Chang et al., 2006) : a dramatic increase of brain BNDF that can compensate the deficit of this neurotrophin reported in the MeCP2 mutants in selected brain areas (Pietropaolo et al., 2004; Branchi et al., 2006; Zhu et al., 2006; Sale et al., 2007) . In fact, a trend towards increased life span, as well as improved locomotor activity and motor coordination have been reported when both the MeCP2Bird model (from PND 0) (Pizzorusso et al., 2007 ) and the MeCP2Jae model (from PND 21) were provided with social and physical enriched environments.
Future perspectives
The discovery that RTT is caused by mutations that affect the MeCP2 gene, and the subsequent creation of RTT mouse models, has provided a major breakthrough in understanding this severe neurodevelopmental disorder. Many steps forward have been made and, more importantly, many indications are available that this research field could rapidly progress and that the translation of basic research into efficient pharmacological interventions for RTT patients can be achieved.
This optimism emerges from recent and strong evidence from mouse models showing that RTT is reversible even at a mature stage in both MeCP2Bird and MeCP2Jae models. Moreover, as recent studies support the presence of subtle deficits during that phase earlier regarded as asymptomatic, the presymptomatic stage is now expected to provide an early window of opportunity on which potential therapies could be tested.
To successfully achieve the ambitious aim of finding a cure for RTT patients, transnational collaborative networks are, however, mandatory. As a matter of fact, RTT is a rare disease affecting one in 10 000 girls. This fact inevitably limits clinical studies and so the first European multidisciplinary network on RTT (EuroRETT, E-RARE program) has recently been created. This transnational network is expected to promote the development of an international database for studying phenotype-genotype correlations as well as to combine different expertise for a better understanding of the syndrome.
In conclusion, the discovery of a monogenic origin for RTT has actually provided to basic and clinical research the necessary tools for understanding, and hopefully treating, this devastating syndrome. Future research efforts can therefore be anticipated to make significant progress towards providing a better quality of life for girls with RTT.
